$3.84
+0.07 (+1.80%)
USD · as of 2026-08-07 · marketstack
stale — last close 2026-08-07, not a live quote
Clinical trials
catalyst calendar across sponsors →Studies where PSTV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 7.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentNCT05460507Assessment of safety and tolerability of a second dose of 186RNL by CED as part of standard of care >30 days following first dose.Open-label · Treatment | Phase 1 | Recruiting | Drug: Retreatment Rhenium Liposome | Glioma | 40 | 2028-03-01 | in 560 d | 2025-03-30 |
| Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade GliomaNCT07061626Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: Rhenium-186 Nanoliposome | Ependymoma, High Grade Gliomas | 56 | Mar 2027 | ≤ 224 d | 2025-07-11 |
| Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesNCT07098806Maximum Tolerated DoseOpen-label · Treatment | Phase 1 | Recruiting | Drug: 186RNL | Leptomeningeal Metastasis | 24 | 2026-10-02 | in 44 d | 2025-08-01 |
| Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)NCT01906385Phase 1: Maximum Tolerated DoseOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: Rhenium Liposome Treatment | Glioma | 55 | Dec 2025 | — | 2025-03-26 |
| Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesNCT05034497Incidence and severity of adverse events (AE) and serious adverse events (SAE)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: 186RNL | Leptomeningeal Metastasis | 18 | 2025-12-21 | — | 2025-03-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19